| Patient-derived tumour xenografts as models for oncology drug development JJ Tentler, AC Tan, CD Weekes, A Jimeno, S Leong, TM Pitts, JJ Arcaroli, ... Nature reviews Clinical oncology 9 (6), 338-350, 2012 | 1365 | 2012 |
| Gastric cancer, version 3.2016, NCCN clinical practice guidelines in oncology JA Ajani, TA D'Amico, K Almhanna, DJ Bentrem, J Chao, P Das, ... Journal of the National Comprehensive Cancer Network 14 (10), 1286-1312, 2016 | 916 | 2016 |
| Esophageal and esophagogastric junction cancers, version 2.2019, NCCN clinical practice guidelines in oncology JA Ajani, TA D’Amico, DJ Bentrem, J Chao, C Corvera, P Das, ... Journal of the National Comprehensive Cancer Network 17 (7), 855-883, 2019 | 797 | 2019 |
| Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with … AA Adjei, RB Cohen, W Franklin, C Morris, D Wilson, JR Molina, ... Journal of clinical oncology: official journal of the American Society of …, 2008 | 691 | 2008 |
| Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 JL Spratlin, RB Cohen, M Eadens, L Gore, DR Camidge, S Diab, S Leong, ... Journal of Clinical Oncology 28 (5), 780, 2010 | 676 | 2010 |
| Esophageal and esophagogastric junction cancers, version 1.2015 JA Ajani, TA D’Amico, K Almhanna, DJ Bentrem, S Besh, J Chao, P Das, ... Journal of the National Comprehensive Cancer Network 13 (2), 194-227, 2015 | 378 | 2015 |
| Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised … CS Fuchs, K Shitara, M Di Bartolomeo, S Lonardi, SE Al-Batran, ... The Lancet Oncology 20 (3), 420-435, 2019 | 226 | 2019 |
| A phase I study of weekly R1507, a human monoclonal antibody insulin-like growth factor-I receptor antagonist, in patients with advanced solid tumors R Kurzrock, A Patnaik, J Aisner, T Warren, S Leong, R Benjamin, ... Clinical Cancer Research 16 (8), 2458-2465, 2010 | 212 | 2010 |
| Mapatumumab, an antibody targeting TRAIL-R1, in combination with paclitaxel and carboplatin in patients with advanced solid malignancies: results of a phase I and … S Leong, RB Cohen, DL Gustafson, CJ Langer, DR Camidge, K Padavic, ... Journal of clinical oncology 27 (26), 4413-4421, 2009 | 161 | 2009 |
| Metaanalysis of survival, complications, and imaging response following chemotherapy-based transarterial therapy in patients with unresectable intrahepatic cholangiocarcinoma CE Ray Jr, A Edwards, MT Smith, S Leong, K Kondo, M Gipson, ... Journal of Vascular and Interventional Radiology 24 (8), 1218-1226, 2013 | 94 | 2013 |
| Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development TM Pitts, AC Tan, GN Kulikowski, JJ Tentler, AM Brown, SA Flanigan, ... Clinical cancer research 16 (12), 3193-3204, 2010 | 93 | 2010 |
| Identification of Predictive Markers of Response to the MEK1/2 Inhibitor Selumetinib (AZD6244) in K-ras–Mutated Colorectal Cancer JJ Tentler, S Nallapareddy, AC Tan, A Spreafico, TM Pitts, MP Morelli, ... Molecular cancer therapeutics 9 (12), 3351-3362, 2010 | 91 | 2010 |
| A multi-arm phase I study of the PI3K/mTOR inhibitors PF-04691502 and gedatolisib (PF-05212384) plus irinotecan or the MEK inhibitor PD-0325901 in advanced cancer ZA Wainberg, M Alsina, HP Soares, I Braña, CD Britten, G Del Conte, ... Targeted oncology 12, 775-785, 2017 | 80 | 2017 |
| Phase I study of oral rigosertib (ON 01910. Na), a dual inhibitor of the PI3K and Plk1 pathways, in adult patients with advanced solid malignancies DW Bowles, JR Diamond, ET Lam, CD Weekes, DP Astling, RT Anderson, ... Clinical Cancer Research 20 (6), 1656-1665, 2014 | 70 | 2014 |
| Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models SA Flanigan, TM Pitts, TP Newton, GN Kulikowski, AC Tan, MC McManus, ... Clinical cancer research 19 (22), 6219-6229, 2013 | 62 | 2013 |
| OX40 agonist BMS-986178 alone or in combination with nivolumab and/or ipilimumab in patients with advanced solid tumors M Gutierrez, V Moreno, KM Heinhuis, AJ Olszanski, A Spreafico, M Ong, ... Clinical Cancer Research 27 (2), 460-472, 2021 | 61 | 2021 |
| From bench to bedside: lessons learned in translating preclinical studies in cancer drug development CH Lieu, AC Tan, S Leong, JR Diamond, SG Eckhardt Journal of the National Cancer Institute 105 (19), 1441-1456, 2013 | 61 | 2013 |
| Development of new preclinical models to advance adrenocortical carcinoma research K Kiseljak-Vassiliades, Y Zhang, SM Bagby, A Kar, N Pozdeyev, M Xu, ... Endocrine-Related Cancer 25 (4), 437-451, 2018 | 60 | 2018 |
| Multidisciplinary management for esophageal and gastric cancer MM Boniface, SB Wani, TE Schefter, PJ Koo, C Meguid, S Leong, ... Cancer management and research, 39-44, 2016 | 59 | 2016 |
| A phase I dose-escalation, safety and pharmacokinetic study of the 2-methoxyestradiol analog ENMD-1198 administered orally to patients with advanced cancer Q Zhou, D Gustafson, S Nallapareddy, S Diab, S Leong, K Lewis, L Gore, ... Investigational new drugs 29, 340-346, 2011 | 56 | 2011 |
